New targets for type 2-low asthma
Asthma is characterized by airway obstruction and inflammation, and presents significant diagnostic and treatment challenges. The concept of endotypes has improved understanding of the mechanisms of asthma and has stimulated the development of effective treatment strategies. Sputum profiles may be u...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Association of Internal Medicine
2024-03-01
|
| Series: | The Korean Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://www.kjim.org/upload/kjim-2023-299.pdf |
| _version_ | 1797279276837371904 |
|---|---|
| author | Quang Luu Quoc Youngwoo Choi Gyu-Young Hur Hae-Sim Park |
| author_facet | Quang Luu Quoc Youngwoo Choi Gyu-Young Hur Hae-Sim Park |
| author_sort | Quang Luu Quoc |
| collection | DOAJ |
| description | Asthma is characterized by airway obstruction and inflammation, and presents significant diagnostic and treatment challenges. The concept of endotypes has improved understanding of the mechanisms of asthma and has stimulated the development of effective treatment strategies. Sputum profiles may be used to classify asthma into two major inflammatory types: type 2-high (T2H) and type 2-low (T2L) asthma. T2H, characterized by elevated type 2 inflammation, has been extensively studied and several effective biologic treatments have been developed. However, managing T2L is more difficult due to the lack of reliable biomarkers for accurate diagnosis and classification. Additionally, conventional anti-inflammatory therapy does not completely control the symptoms of T2L; therefore, further research is needed to identify effective biologic treatments. This review provides new insights into the clinical characteristics and underlying mechanisms of severe T2L and investigates potential therapeutic approaches to control the disease. |
| first_indexed | 2024-03-07T16:22:57Z |
| format | Article |
| id | doaj.art-b669b7d0036f454cb4ca9160f9674cad |
| institution | Directory Open Access Journal |
| issn | 1226-3303 2005-6648 |
| language | English |
| last_indexed | 2024-03-07T16:22:57Z |
| publishDate | 2024-03-01 |
| publisher | The Korean Association of Internal Medicine |
| record_format | Article |
| series | The Korean Journal of Internal Medicine |
| spelling | doaj.art-b669b7d0036f454cb4ca9160f9674cad2024-03-04T04:15:54ZengThe Korean Association of Internal MedicineThe Korean Journal of Internal Medicine1226-33032005-66482024-03-0139221522710.3904/kjim.2023.299170893New targets for type 2-low asthmaQuang Luu Quoc0Youngwoo Choi1Gyu-Young Hur2Hae-Sim Park3 Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea Department of Biomaterials Science (BK21 FOUR Program), College of Natural Resources and Life Science, Pusan National University, Miryang, Korea Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, KoreaAsthma is characterized by airway obstruction and inflammation, and presents significant diagnostic and treatment challenges. The concept of endotypes has improved understanding of the mechanisms of asthma and has stimulated the development of effective treatment strategies. Sputum profiles may be used to classify asthma into two major inflammatory types: type 2-high (T2H) and type 2-low (T2L) asthma. T2H, characterized by elevated type 2 inflammation, has been extensively studied and several effective biologic treatments have been developed. However, managing T2L is more difficult due to the lack of reliable biomarkers for accurate diagnosis and classification. Additionally, conventional anti-inflammatory therapy does not completely control the symptoms of T2L; therefore, further research is needed to identify effective biologic treatments. This review provides new insights into the clinical characteristics and underlying mechanisms of severe T2L and investigates potential therapeutic approaches to control the disease.http://www.kjim.org/upload/kjim-2023-299.pdfasthmabiomarkermechanismneutrophiltherapeutics |
| spellingShingle | Quang Luu Quoc Youngwoo Choi Gyu-Young Hur Hae-Sim Park New targets for type 2-low asthma The Korean Journal of Internal Medicine asthma biomarker mechanism neutrophil therapeutics |
| title | New targets for type 2-low asthma |
| title_full | New targets for type 2-low asthma |
| title_fullStr | New targets for type 2-low asthma |
| title_full_unstemmed | New targets for type 2-low asthma |
| title_short | New targets for type 2-low asthma |
| title_sort | new targets for type 2 low asthma |
| topic | asthma biomarker mechanism neutrophil therapeutics |
| url | http://www.kjim.org/upload/kjim-2023-299.pdf |
| work_keys_str_mv | AT quangluuquoc newtargetsfortype2lowasthma AT youngwoochoi newtargetsfortype2lowasthma AT gyuyounghur newtargetsfortype2lowasthma AT haesimpark newtargetsfortype2lowasthma |